Literature DB >> 18997183

Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.

Naruto Taira1, Shozo Ohsumi, Daisuke Takabatake, Fumikata Hara, Seiki Takashima, Kenjiro Aogi, Shigemitsu Takashima, Takeshi Inoue, Shigenori Sugata, Rieko Nishimura.   

Abstract

OBJECTIVE: Sentinel node biopsy (SNB) is indicated for axillary lymph node metastasis-negative cases (N0), but clarification of the indication may increase treatment efficiency. Fluorine-18-labeled 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) may have a high positive predictive value in diagnosis of axillary lymph node metastasis.
METHODS: Ninety-two breasts/axillae were analyzed retrospectively in 90 patients (median age 54.6-year old, median primary tumor 1.7 cm). FDG-PET/computed tomography was used to indicate SNB in N0 cases. Axillary lymph node dissection (ALND) was performed in cases that were axillary lymph node metastasis-positive (PET N+) on FDG-PET/CT.
RESULTS: Seventy-four (80.4%) and 18 (19.6%) of the 92 axillae were diagnosed as metastasis-negative (PET N0) and PET N+, respectively, by FDG-PET/CT. SNB was performed in 51 of the 74 PET N0 axillae. ALND was performed in 23 PET N0 axillae (at the patients' request) and in all 18 PET N+ axillae. Of the 74 PET N0 axillae, 14 were metastasis-positive (pN+) and 60 were pN0 pathologically, and of the 18 PET N+ axillae, 13 were pN+ and five were pN0. The sensitivity and specificity of FDG-PET/CT for diagnosis of axillary metastasis were 48.1 and 92.3%, respectively, and the positive and negative predictive values were 72.2 and 81.1%, respectively.
CONCLUSION: The positive detection rate on FDG-PET/CT was insufficient for determining an indication of SNB. However, use of an appropriate cut-off for SUV(max) (the positive rate was 90.9% with a cut-off of 2.0) and exclusion of surgically biopsied cases may achieve a clinically applicable positive detection rate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997183     DOI: 10.1093/jjco/hyn120

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?

Authors:  Selin Carkaci; Beatriz E Adrada; Eric Rohren; Wei Wei; Mohammad A Quraishi; Osama Mawlawi; Thomas A Buchholz; Wei Yang
Journal:  Acad Radiol       Date:  2012-02-01       Impact factor: 3.173

Review 2.  Present and future role of FDG-PET/CT imaging in the management of breast cancer.

Authors:  Kazuhiro Kitajima; Yasuo Miyoshi
Journal:  Jpn J Radiol       Date:  2016-01-05       Impact factor: 2.374

Review 3.  Positron emission tomography for benign and malignant disease.

Authors:  Anthony Visioni; Julian Kim
Journal:  Surg Clin North Am       Date:  2011-02       Impact factor: 2.741

4.  Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors.

Authors:  Ana María García Vicente; Angel Soriano Castrejón; Miguel Angel Cruz Mora; Ana González Ageitos; María del Mar Muñoz Sánchez; Alberto León Martín; Ruth Espinosa Aunión; Fernanda Relea Calatayud; Vicente Muñoz Madero; Ignacio Chacón López-Muñiz; Jose Manuel Cordero García; Germán Andrés Jiménez Londoño
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-28       Impact factor: 9.236

5.  Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer.

Authors:  Kazuhiro Kitajima; Kazuhito Fukushima; Yasuo Miyoshi; Takayuki Katsuura; Yoko Igarashi; Yusuke Kawanaka; Miya Mouri; Kaoru Maruyama; Toshiko Yamano; Hiroshi Doi; Koichiro Yamakado; Seiichi Hirota; Shozo Hirota
Journal:  Jpn J Radiol       Date:  2015-12-29       Impact factor: 2.374

6.  Normal Physiologic and Benign Foci with F-18 FDG Avidity on PET/CT in Patients with Breast Cancer.

Authors:  Soon-Ah Park; Kwang-Man Lee; UnJong Choi; Hun Soo Kim; Hye-Won Kim; Jeong Hoon Song
Journal:  Nucl Med Mol Imaging       Date:  2010-10-16

7.  Early SUVmax is the best predictor of axillary lymph node metastasis in stage III breast cancers.

Authors:  Jiangong Zhang; Xun Shi; Yong Xiao; Chao Ma; Gang Cao; Yongbo Liu; Yonggang Li
Journal:  Quant Imaging Med Surg       Date:  2021-05

8.  3D reconstruction based novel methods are more effective than traditional clinical assessment in breast cancer axillary lymph node metastasis prediction.

Authors:  Limeng Qu; Qitong Chen; Na Luo; Piao Zhao; Qiongyan Zou; Xilong Mei; Ziru Liu; Wenjun Yi
Journal:  Sci Rep       Date:  2022-07-20       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.